Showing results (291-300 of 425) with videos related to

Sort By:
Pageof 43
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJarrod P Holmes, Linda C Benavides, Jeremy D Gates, et al.
Annals of Surgical Oncology|April 24, 2015
Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?Ashleigh M Francis, Christine E Haugen, Lynn M Grimes, et al.
The Oncologist|April 12, 2013
Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancerJennifer K Litton, Carla L Warneke, Karin M Hahn, et al.
Annals of Surgical Oncology|January 22, 2026
Evaluating the Impact of a Surgeon-Led Ductal Carcinoma in Situ Program on Endocrine Therapy UptakeMonika K Masanam, Olga Kantor, Olivia Pappas Brunco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomesElizabeth A Mittendorf, Yun Wu, Maurizio Scaltriti, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancerSonia Pernas, Jennifer L Guerriero, Sergey Naumenko, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2008
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Asna Amin, Linda C Benavides, Jarrod P Holmes, et al.
Annals of Surgical Oncology|August 24, 2011
Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapyCatherine L Akay, Funda Meric-Bernstam, Kelly K Hunt, et al.
Annals of Surgical Oncology|December 31, 2023
Defining the Biology of Estrogen Receptor-Low-Positive Breast CancerTessa Higgins, Olga Kantor, Beth Harrison, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2024
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancerPaolo Tarantino, Ogheneochuko Ajari, Noah Graham, et al.
Pageof 43